Preview Newsletter

XARELTO Media Monitoring – Week of 9-4-15

Plaintiff Attorney Press Releases

Xarelto Lawsuit Update: Wrongful Death Lawsuit Filed in Vermont
Sep 1, 2015 | WHNS-TV
By Marc Goldich

BloodThinnerHelp.com reports on the increasing number of mass tort lawsuits are being filed against Bayer AG and Johnson&Johnson and one recently filed in Vermont. These lawsuits all generally allege that the blood thinner, Xarelto, caused uncontrollable internal bleeding which lead to patients suffering from severe injuries, hospitalization, and even death in some cases. A lawsuit has been filed in Vermont federal court with the case number 2:14-CV-00159-CR on July 25, 2014 making these allegations against Xarelto’s manufacturers.
Xareltoinjurylawsuits.info Bares All about Xarelto’s Drug Trial Misconduct and Deceptive Marketing Controversies
Sep 2, 2015 | PR Buzz
By Meldofsky Firm

While patients and medical health professionals are at a look out for more effective and cost-efficient treatment for various disorders, drug manufacturers have the responsibility to provide the public with facts about the pharmaceutical and clinical trials for every drug and substance that is marketed for public consumption. And, for one, Xarelto has been labeled as such because of the incidences that brought people to file and join the campaign to file a Xarelto lawsuit against the drug company who manufactured and distributed the drug.
Xarelto Lawsuit Update: Number of Cases in MDL Growing Exponentially
Sep 3, 2015 | WAND-17
By Marc Goldich

BloodThinnerHelp.com reports on the growing number of Xarelto lawsuits filed in the federal MDL. Within the past month, more than 400 additional lawsuits have been consolidated into the Xarelto multidistrict litigation. These lawsuits all make similar allegations that Xarelto usage caused serious side effects and uncontrollable internal bleeding.
Xarelto Lawsuit Update: Wrongful Death Lawsuit Filed in Florida
Sep 3, 2015 | WDRB.com
By Marc Goldich

BloodThinnerHelp.com reports on a Xarelto lawsuit filed in Florida by the widower of a Florida man alleging that the drug was the cause of her late husband’s severe internal bleeding that led to his serious injury and eventual death. The lawsuit was filed on June 23, 2014 in the United States District Court for the Southern District of Florida against the drug conglomerates Bayer AG and Johnson&Johnson under the case number 9:14CV80831. You can download the full official complaint here.
Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings
Sep 4, 2015 | PR Newswire
By Fair Rate Funding

Fair Rate Funding, a lawsuit funding firm located in Manasquan, New Jersey, reports a dramatic increase in lawsuit filings in connection with the blood thinning drug, Xarelto. The number of filed Xarelto lawsuits in the Philadelphia Court of Common Pleas has risen in recent months to over 300 cases. In the Louisiana multi---district litigation (MDL), located in the US District Court for the Eastern District of Louisiana, the filings are also on the rise, numbering over 400 cases. Some sources indicate over 1,200 Xarelto product liability lawsuits have already been filed nationwide.

Plaintiff Attorney Blog Posts

Xarelto Lawsuit Progress Update
Aug 28, 2015 | Dyer, Garofalo, Mann & Schultz L.P.A.

Popular blood thinner Xarelto is facing the pressure of serious lawsuits. The drug is manufactured by Janssen Pharmaceuticals, a New Jersey-based arm of Bayer and Johnson & Johnson.
Xarelto Lawsuit Representation
Aug 28, 2015 | Cueria Law Firm L.L.C.

The Doctor/patient relationship is one based on a foundation of trust. When a pharmaceutical company takes advantage of this relationship and puts patients at risk, they should be held accountable. There are reasons that a new drug has many trials, to ensure that it actually does what the manufacturer claims. When a company fails to thoroughly test their product, they are risking the lives of their patients.
Bayer and Janssen Sued over Alleged Xarelto-related Complications
Aug 29, 2015 | Danziger & De Llano, LLP

Illinois – A consumer is suing the manufacturers of anticoagulant medication Xarelto over alleged damages attributed to the use of the product from 2011. Daniel Hernandez, a Rhode Island resident, has filed a complaint against the following pharmaceutical companies: Janssen Ortho; Janssen Research and Development; Janssen Pharmaceuticals; and Bayer Corporation and several of its United States subsidiaries. The lawsuit was filed in February in the circuit court of St. Clair County.
Xarelto MDL Gathers Steam
Aug 30, 2015 | LawyersandSettlements.com
By Heidi Turner

If you thought the number of Xarelto lawsuits filed was about to slow down, you might have to think again. In the past month, another 400 or so lawsuits have been added to the Xarelto multidistrict litigation, alleging patients suffered serious Xarelto side effects, including uncontrolled bleeding. According to court documents, 1,231 lawsuits have been consolidated for pretrial proceedings in MDL 2592 (In Re: Xarelto (Rivaroxaban) Products Liability Litigation) as of August 17, 2015. That’s up from 805 lawsuits consolidated as of July 15, 2015 and well up from the around 500 lawsuits consolidated in June. Consolidation of lawsuits is done when lawsuits share similar questions of fact and is not a comment on the merits of the individual suits.
The rise of Xarelto litigation
Aug 31, 2015 | APSense
By Mickey Andersonn

Since the filing of the first Xarelto lawsuit in January 2014, a large number of cases have been filed against the manufacturer of the blood-thinning drug. With so many lawsuits, the U.S. Judicial Panel decided to form a multi-district litigation mechanism to streamline the discovery phases of the litigation. At the time of the approval of the multi-district litigation, there were almost 21 lawsuits pending in 10 districts. As per the Judicial Panel on Multidistrict Litigation’s monthly report, almost 86 lawsuits were pending as of January 15, 2015, in multi-district litigation before US District Judge Eldon E. Fallon, in the Eastern District for Louisiana. In May 2015, a total number of 434 lawsuits had been filed, as against 33 in December 2014.
Xarelto Lawsuits Update: Texas Woman Files Lawsuit Against Xarelto Manufacturers
Aug 31, 2015 | The Legal Herald
By Marc Goldich

BloodThinnerHelp.com reports today on the latest developments in the Xarelto litigation. Recently, the manufacturers of Xarelto, Bayer AG and Johnson & Johnson’s pharmaceutical department, Janssen Pharmaceuticals, have been sued in federal court in the Eastern District of New York by a woman in Texas who alleges that because of the manufacturer’s lack of warning regarding Xarelto’s side effects and the lack of sufficient safety testing on the drug, she suffered serious injuries. The complaint is listed under federal court docket number 1:14-CV-04524 and has been transferred to the Xarelto MDL.
Xarelto Studies Point to Increased Bleeding Risk
Sep 2, 2015 | Top Class Actions
By Karina Basso

Researchers have published two new studies regarding the controversial anticoagulant medication Xarelto, raising more concerns about the uncontrollable bleeding side effects associated with the blood thinner. Both of these recent Xarelto studies link the drug, manufactured by Janssen Pharmaceuticals, with bleeding side effects that can lead to fatal consequences for patients.
Xarelto Dangers Outlined In Lawsuit
Sep 2, 2015 | American Injury Attorney Group

Xarelto lawyers note the Xarelto dangers that were outlined in allegations contained in a woman’s lawsuit filed against drug makers Janssen Pharmaceuticals and Bayer AG. The July 2015 lawsuit, filed in federal court for the Eastern District of New York, claims that the drug makers were negligent in failing to perform sufficient safety tests on the drug. If you or a loved one took Xarelto and suffered complications, contact the American Injury Attorney Group today to learn more about your options. We can answer your questions in a free, confidential, no-obligation consultation, and if you wish to pursue a claim, we can connect you with an affiliated Xarelto lawsuit attorney.
FDA Reviewers: Warfarin is Better than Xarelto for Stroke Patients
Sep 2, 2015 | Meldofsky Firm

The blood thinner drug sold under the name Xarelto (Rivaroxiban) has been criticized by reviewers from the U.S. Food and Drug Administration (FDA) for what they’re calling a lack of efficacy in preventing stroke in certain patients. Physicians prescribe Xarelto for stroke prevention in people with non-valvular atrial fibrillation or “AF”. This conclusion was the result of a meeting of the FDA Cardiovascular and Renal Drugs Advisory Committee, a group that reviews prescription drugs and makes recommendations as to whether a particular medication should be approved for a specific indication or ailment.
Patient Questions Bleeding Side Effects With Blood Thinner Xarelto
Sep 3, 2015 | Righting Injustice
By Jennifer Walker-Journey

E.H., a healthy 79-year-old man, is questioning whether he should take the new blood thinner Xarelto to treat occasional atrial fibrillation considering his history with bleeding events. “I hear it can be dangerous,” E.H. told Dr. Roach in a regular medical advice column in The Detroit News. “My doctors don’t seem worried, but I am.” E.H. says he has suffered from rectal bleeding in the past, “which wasn’t serious, but was scary.” He can’t even take aspirin because he’s prone to throwing up blood. He’s read enough about the new anticoagulant to question whether he should be concerned about taking Xarelto.
Widow Files Xarelto Bleeding Wrongful Death Lawsuit
Sep 4, 2015 | Top Class Actions
By Ashley Vanover

Bayer and Johnson & Johnson are facing a wrongful death lawsuit, alleging that their blood thinner Xarelto (rivaroxaban) is dangerous and should not be sold. A Florida widow filed a Xarelto bleeding wrongful death lawsuit on behalf of her deceased husband, Ronald H. against the manufacturer Janssen Pharmaceutical, a subsidiary of Johnson & Johnson and the co-marketer of Xarelto, and Bayer Healthcare AG, alleging these companies failed to warn of the increased risks of irreversible internal bleeding when using Xarelto.

Plaintiff Attorney Press Releases

Xarelto Lawsuit Update: Wrongful Death Lawsuit Filed in Vermont

Sep 1, 2015 | WHNS-TV

By Marc Goldich

September 01, 2015 – /PressAdvantage/ – BloodThinnerHelp.com reports on the increasing number of mass tort lawsuits are being filed against Bayer AG and Johnson&Johnson and one recently filed in Vermont. These lawsuits all generally allege that the blood thinner, Xarelto, caused uncontrollable internal bleeding which lead to patients suffering from severe injuries, hospitalization, and even death in some cases. A lawsuit has been filed in Vermont federal court with the case number 2:14-CV-00159-CR on July 25, 2014 making these allegations against Xarelto’s manufacturers.
Wrongful Death Lawsuit Filed in Vermont Federal Court:
Specifically, the lawsuit was brought to court by the daughter of a deceased man who was prescribed Xarelto to prevent blood clots and stroke due to atrial fibrillation, a heart condition he suffered from. In the complaint, it states that the deceased was prescribed Xarelto (rivaroxaban) on July 17, 2012 and regularly took the drug until he was admitted to the hospital and diagnosed with a parenchymal hemorrhage. Because the deceased was regularly taking Xarelto, it was active in his system at the time of the injury and his blood did not clot. Tragically, after six days in the hospital, he died from the uncontrollable internal bleeding event on August 1, 2012. The complaint alleges that his death was caused by Xarelto usage.
Lawsuit Alleges that Xarelto Caused Brain Bleed:
The adverse event the deceased suffered from, a parenchymal hemorrhage, is one of the most severe brain bleeds. It is an immediate medical emergency and can be caused by trauma such as a fall or car accident or hypertension. A hemorrhage in the brain disrupts and compresses brain tissue, causing the brain to malfunction. The presence of a blood thinner in the patient’s system prevented the blood from clotting to stop the bleed and as a result, blood pooled in the brain parenchyma. This causes a dramatic increase in intracranial pressure and herniation. This event often results in death and extreme life saving measures are required for treatment of the condition because it is so difficult to detect before it is too late.
Wrongful Death Lawsuits Filed Against Xarelto:
Relatives of a deceased person who has died due to injuries related to Xarelto have the right to file a wrongful death lawsuit, as the Vermont woman who lost her father did. She is bringing the lawsuit to court as the administrator of his estate and is seeking damages for pain and suffering, medical expenses, probate, attorney fees, funeral expenses, and all other expenses related to the probate of his estate. The complaint filed alleges that if the woman and her father had known the risks Xarelto presents for an irreversible bleed, they would have not chosen to use the drug because of the safer alternatives on the market. They allege that the manufacturers of Xarelto were reckless by distributing the drug on the market, which was essentially the cause of the injuries and ultimately the death of the deceased.
“If the drug manufacturers did indeed know of Xarelto’s dangers, they should be held responsible for their actions,” Xarelto attorney Marc Goldich says. “We encourage anyone who has suffered injuries due to Xarelto usage to contact us and consider filing a lawsuit.”
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.foxcarolina.com/story/29935644/xarelto-lawsuit-update-wrongful-death-lawsuit-filed-in-vermont#ixzz3khS8OfOI

Return to headline | Return to top
Xareltoinjurylawsuits.info Bares All about Xarelto’s Drug Trial Misconduct and Deceptive Marketing Controversies

Sep 2, 2015 | PR Buzz

By Meldofsky Firm

While patients and medical health professionals are at a look out for more effective and cost-efficient treatment for various disorders, drug manufacturers have the responsibility to provide the public with facts about the pharmaceutical and clinical trials for every drug and substance that is marketed for public consumption.
And, for one, Xarelto has been labeled as such because of the incidences that brought people to file and join the campaign to file a Xarelto lawsuit against the drug company who manufactured and distributed the drug.
One of the facts that has made Xarelto more controversial is that Charles Seife stated in his study which was published by JAMA Internal Medicine specifically stated the flaws on what and how consumers of this drug obtain information about Xarelto’s clinical trials; and that this was done profoundly. With the very vague information that was released about the drug, controversies have become more and more such as the inaccuracy of the records of the trials done on the drug and the provision of false data, deviated pharmaceutical trial protocol, and the failure of those conducting the trial to protect their subjects’ safety.
Clinical research misconduct is not a new thing when it comes to seeking approval; and license from the FDA, but with the alarming number of Xarelto users experiencing adverse reactions and untoward side effects from the drug it has compelled people to file their case against the company through a Xarelto lawyer. These lawyers would do everything to assist the patients through the entire legal process so that they may be given due compensation for the harmful effects of the drug.
In the issue brought out by Seife, he questions why the FDA has withheld these gravely serious proofs of drug trial misconduct by the makers and manufacturers of Xarelto; wherein fact they should be protecting the welfare and safety of the patients. However, even if Xarelto has been legally distributed and used for treatment because of its promising effective therapeutic claims, hundreds of lawsuits were filed against Bayer Pharmaceuticals and Janssen.
The case against these companies is basically about their deceptive marketing and their failure to provide the public about the bleeding tendencies that Xarelto may have on its consumers. This has been evidenced by patients being discovered and diagnosed to have cerebral hemorrhage, gastrointestinal bleeding, etc; and for a fact, this has put the lives of the patients who were given the drug in a great risk of fatality. And because Xarelto has no known antidote, the effects of the drug could not easily be reversed.
About Xarelto Injury Lawsuits Info
Xarelto Injury Lawsuits Info is an online resource center created by The Meldofsky Firm. They are passionate about ensuring that clients both present and potential are furnished with the resources and services they need to seek compensation following an injury or wrongful death.
https://www.prbuzz.com/health-a-fitness/345433-xareltoinjurylawsuits-info-bares-all-about-xareltos-drug-trial-misconduct-and-deceptive-marketing-controversies.html

Return to headline | Return to top
Xarelto Lawsuit Update: Number of Cases in MDL Growing Exponentially

Sep 3, 2015 | WAND-17

By Marc Goldich

September 02, 2015 – /PressAdvantage/ – BloodThinnerHelp.com reports on the growing number of Xarelto lawsuits filed in the federal MDL. Within the past month, more than 400 additional lawsuits have been consolidated into the Xarelto multidistrict litigation. These lawsuits all make similar allegations that Xarelto usage caused serious side effects and uncontrollable internal bleeding.
Court documents show that as of August, 17 2015, 1,231 total lawsuits at this time have been consolidated into MDL 2592 for pretrial proceedings. This is a huge increase from the data released on July 15, 2015 that showed only 805 consolidated lawsuits, and an even larger increase from June where there were only about 500 lawsuits in the MDL. These lawsuits all commonly allege that Xarelto users suffered from uncontrollable internal bleeding events because the manufacturers of the drug did not sufficiently warn patients of the risks associated with Xarelto.
Xarelto Usage Linked to Serious Side Effects:
Xarelto, a prescription anticoagulant made up of the generic drug rivaroxaban, was released onto the United States market after the FDA approved the drug in 2011. Since then, Xarelto’s manufacturers, Bayer AG and Johnson&Johnson, have marketed the drug as a safe and more convenient alternative to the traditional blood thinner Warfarin because Xarelto does not require regular blood monitoring like Warfarin does.
Xarelto, however, is much more dangerous than Warfarin because Xarelto does not have a corresponding antidote that will reverse the drug’s effects. Warfarin’s antidote is vitamin K, so if a patient taking Warfarin suffers an internal bleeding injury, vitamin K can be administered and the blood will be able to clot again. No such antidote exists for Xarelto so if a Xarelto user suffers an internal bleed, there is no antidote to make the blood clot again. Critics of Xarelto state that the internal bleeding risk could potentially be minimized if patients were required to have their blood monitored as they are on Warfarin. They also claim that there is no benefit to take Xarelto over Warfarin, especially considering the lack of antidote. Due to this in addition to Xarelto’s dangerousside effects, there are currently two ‘Black Box’ warnings attached to Xarelto by the FDA. The Black Box warning is the most strict warning the FDA can issue to a drug short of recalling it. The FDA has also issued an official warning letter to Xarelto for minimizing the risks associated with usage of the drug.
Xarelto Lawsuits Allege That Drug Companies Were Negligent:
The lawsuits that have been consolidated into the federal MDL in Louisiana and in the mass tort group in Philadelphia all similarly allege that the manufacturers of Xarelto were aware of the dangers that the drug presented and did not adequately warn the public of them.
“If Xarelto’s manufacturer’s were aware of the dangers that Xarelto presented and deliberately did not inform the public, then they should be held responsible for their actions.” Xarelto attorney Marc Goldich said, “We encourage anyone who believes they have been harmed because of their Xarelto usage to contact us immediately.”
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.wandtv.com/story/29944169/xarelto-lawsuit-update-number-of-cases-in-mdl-growing-exponentially

Return to headline | Return to top
Xarelto Lawsuit Update: Wrongful Death Lawsuit Filed in Florida

Sep 3, 2015 | WDRB.com

By Marc Goldich

September 03, 2015 – /PressAdvantage/ – BloodThinnerHelp.com reports on a Xarelto lawsuit filed in Florida by the widower of a Florida man alleging that the drug was the cause of her late husband’s severe internal bleeding that led to his serious injury and eventual death. The lawsuit was filed on June 23, 2014 in the United States District Court for the Southern District of Florida against the drug conglomerates Bayer AG and Johnson&Johnson under the case number 9:14CV80831. You can download the full official complaint here.
This lawsuit is one of many that have been recently filed that all similarly allege that Xarelto’s dangerous side effects were not adequately reported by the drug manufacturers and that the drug manufacturers were aware of the dangers of Xarelto and deliberately concealed this information from doctors and patients. Specifically, this lawsuit is bringing a claim under the counts of failure to warn, design defect, negligence, negligent design, negligent misrepresentation, breach of warranty, fraud, violation of consumer protection laws, punitive damages, and wrongful death.
Xarelto’s Dangerous Side Effects Allege to Cause Subdural Hemorrhage:
The complaint filed further detailed the deceased’s Xarelto usage. He was prescribed the drug on January 10, 2012 to reduce the risk of blood clots and deep vein thrombosis that could be caused by his atrial fibrillation. The deceased then suffered from a subdural hemorrhage, a bleed outside of the brain. He was hospitalized for several days and underwent a right frontal bur hold with evacuation as doctors attempted to stop the severe bleeding. On June 28, 2012, the patient died as a result of complications from the bleed. The complaint alleges that Xarelto was the cause of the subdural hemorrhage and that the deceased would not have taken Xarelto if he was aware of the risks associated with the drug.
A subdural hemorrhage, or a subdural hematoma, can be caused by anything from head trauma to light activity gone wrong. Age can also cause the veins around the brain to stretch and eventually tear, which will cause blood to fill the space around the brain and put dangerous pressure on the brain tissue. It is a very serious medical condition that often leads to a serious stroke or death. If a patient who is taking Xarelto suffers from a subdural hematoma, extreme measures will be required to try to stop the bleeding because Xarelto has no antidote drug.
Families of Xarelto Victims File Wrongful Death Lawsuits:
The plaintiff and her family are bringing this wrongful death lawsuit against Xarelto’s manufacturers alleging that they concealed infromation about Xarelto’s serious risks. A wrongful death lawsuit against Xarelto gives loved ones of the deceased and the estate the opportunity to gain financial compensation for medical, burial and funeral expenses, loss of future income, support, and companionship.
“We strongly encourage all families who have lost a loved one due to complications surrounding Xarelto usage to contact us and consider filing a lawsuit.” experienced Xarelto attorney Marc Goldich said.
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.wdrb.com/story/29953164/xarelto-lawsuit-update-wrongful-death-lawsuit-filed-in-florida

Return to headline | Return to top
Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings

Sep 4, 2015 | PR Newswire

By Fair Rate Funding

Fair Rate Funding, a lawsuit funding firm located in Manasquan, New Jersey, reports a dramatic increase in lawsuit filings in connection with the blood thinning drug, Xarelto. The number of filed Xarelto lawsuits in the Philadelphia Court of Common Pleas has risen in recent months to over 300 cases. In the Louisiana multi---district litigation (MDL), located in the US District Court for the Eastern District of Louisiana, the filings are also on the rise, numbering over 400 cases. Some sources indicate over 1,200 Xarelto product liability lawsuits have already been filed nationwide.
The lawsuits against Bayer and Johnson & Johnson's subsidiary, Janssen Pharmaceutical Division, include claims of serious health problems as a result of using the blood thinner, Xarelto. Plaintiffs allege bleeding events which sometimes even prove fatal. Expert medical professionals opine that there is little that can be done once these bleeding events commence.
Fair Rate Funding specializes in advancing cash now for plaintiffs who are involved in personal injury lawsuits including Xarelto Cases. (See, http://www.fairratefunding.com/pre-settlement-loans.html) For answers to frequently asked Xarelto or lawsuit funding questions, visit: http://professionalsettlementfunding.com/xarelto-lawsuit-funding/
Fair Rate Funding, a lawsuit funding company, has historically been one of the few lawsuit funding companies providing legal financial support in this area. In response to the increasing number of plaintiffs affected by this drug, Fair Rate Funding has allocated additional capital to help plaintiffs pay their living or medical expenses. Thus far, dozens of plaintiffs have utilized this financial lifeline.
Fair Rate Funding's President, Paul Coppola, recognized the serious plight of the plaintiffs, "We are talking about families who may have seen a primary earner die because of this faulty drug. We are talking about people who will have serious issues getting back on their feet. Xarelto lawsuit funding is one available financial option for these plaintiffs."
Fair Rate Funding works diligently to afford lawsuit funding to its applicants, and now has representatives standing by 24 hours a day, 7 days per week in order to answer questions regarding the Xarelto lawsuit funding process.
By offering cash now to help pay for any type of expense such as car loans, rent and mortgage payments, utility payments, personal loans, and daily living expenses, Fair Rate Funding eases some of the financial stress these plaintiffs endure. There are no restrictions on the use of the funds.
Fair Rate Funding stands ready to assist Xarelto lawsuit plaintiffs with a lawsuit cash advance, if they already retained an attorney. To learn more about obtaining lawsuit cash advances on your pharmaceutical lawsuit in general, visit:http://www.fairratefunding.com/product-liability-cases.html
Fair Rate Funding works diligently to afford lawsuit funding to its applicants and has representatives standing by 24 hours a day, seven days a week to answer questions regarding the lawsuit funding process.
Fair Rate Funding's representatives are working around the clock to make sure each and every client gets the attention they need and to see them through to obtaining a cash advance. Fair Rate Funding is able to offer the lowest rates in the industry and makes the process as seamless as possible.
Fair Rate Funding lawsuit settlement funding programs are not a lawsuit loan or lawsuit loans although they are often referred to as such. A pre-settlement lawsuit cash advance is not a settlement loan or settlement loans because the advance is only repaid if the case is successful. Your attorney will repay your case funding or lawsuit advance ONLY if your case is won or settled. Sometimes referred to as settlement loans or lawsuit loans, settlement funding is a purchase of a portion of a future recovery. For answers to the most frequently asked questions about lawsuit funding in general, visit: http://professionalsettlementfunding.com/
Fair Rate Funding prides itself on providing the quickest approvals – as soon as 24 hours on most cases, the lowest monthly usage rates – as low as 2.5% per month, and the most attentive customer service in the lawsuit funding industry. Fair Rate Funding also offers free case evaluations.
For more information about lawsuit funding and other services from Fair Rate Funding, simply call a representative at 888-964-2224 or visit us at http://fairratefunding.com.
http://www.prnewswire.com/news-releases/xarelto-lawsuit-funding-firm-fair-rate-funding-reports-a-steady-rise-in-xarelto-product-liability-lawsuit-filings-300138246.html

Return to headline | Return to top

Plaintiff Attorney Blog Posts

Xarelto Lawsuit Progress Update

Aug 28, 2015 | Dyer, Garofalo, Mann & Schultz L.P.A.

Popular blood thinner Xarelto is facing the pressure of serious lawsuits. The drug is manufactured by Janssen Pharmaceuticals, a New Jersey-based arm of Bayer and Johnson & Johnson.
WHAT IS XARELTO?
Xarelto is a factor Xa inhibitor, a type of anitcoagulant used to block the activity of clotting factor Xa and prevent blood clots from occurring or worsening. In July 2011 Xarelto (Rivaroxaban) was approved by the FDA for treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) after knee and hip replacement surgery. In November 2011 its approval was updated to include prevention of Thromboembolism in Atrial Fibrillation. In November 2012, the FDA expanded the approval to include non-surgical-related treatment of DVT and PE and to reduce the risk of recurrent DVT and PE after initial treatment. In the first year of drug sales in the United States, Xarelto earned $239 million.
Upon its introduction, Xarelto was touted as a promising alternative to warfarin because it did not require the routine monitoring or regulating that Warfarin did. Xarelto could be prescribed in a uniform dose as opposed to older coagulants that required individualized dosing per patient. In the long run, this turned out to more dangerous than advantageous where patients with vast ranges in weight and age were given the same dosage. Without monitoring the monitoring required with older drugs like Warfarin, healthcare providers were unaware of the potential devastating results. In the last four years, patients have made many reports of injury resulting from the drug.
WHY IS XARELTO DANGEROUS?
The biggest complaint against Xarelto is its potential to cause uncontrollable bleeding. Other blood thinners have an antidote – a shot of vitamin K, for example, can stop bleeding caused by warfarin. Xarelto does not. Xarelto has been attributed a myriad of complications such as brain hemorrhage, hemorrhagic stroke, gastrointestinal bleeding, and wound infection and leakage. In many cases, the problems have been severe or even fatal. In 2012, the FDA announced that Xarelto was responsible for three times the fatalities due to adverse effects compared to warfarin.
The FDA denied approval of Xarelto for treatment of patients battling sudden reduced blood flow to the heart, like in the case of a heart attack or chest pain, known as acute coronary syndrome (ACS). The FDA based the denial for ACS treatment on the omission of certain trial date and a deficit in clinical data. Despite garnering the approval for this additional treatment and the initiation of more lawsuits, Xarelto sales continued to climb.
XARELTO LAWSUITS
In 2014, Virginia Stunteneck brought the first lawsuit against drug manufacturers Bayer and Johnson & Johnson in the U.S. District Court of the Eastern District of Pennsylvania. Ms. Stunteneck suffered substantial injuries as a result of taking Xarelto, including hospitalization for severe gastrointestinal bleeding in 2013. Her suit alleged the defendants failed to warn consumers of the potential dangers when the defendants knew or should have known of such problems.
Also in 2014, Ruth McGowan filed a lawsuit against Bayer Healthgroup and Janssen on behalf of her deceased father, Thomas Dunkley. The suit alleged that Mr. Dunkley suffered severe brain bleeding as a result of taking Xarelto for one month. By mid-2015 there were over 2,000 cases filed against the manufacturers of Xarelto. According to legal experts, the litigation is in its infancy and it is expected that several thousand more claims may be filed.
In December 2014, the U.S. Judicial Panel on Multidistrict Litigation consolidated proceedings for all Xarelto injury cases filed in federal court. The cases were centralized in multidistrict litigation (MDL) in the Eastern District of Louisiana. The MDL was ordered to be heard by District Judge Eldon Fallon. In the MDL, the plaintiffs keep their own attorneys but the cases are all handled by the same experienced judge in the same court. Additionally, a mass tort case based upon injuries resulting from Xarelto has been filed in Philadelphia, Pennsylvania.
Judge Fallon has indicated that the main focus for this year in the MDL will be coordination of discovery from the manufacturers. This will entail the review of millions of documents regarding the research, development, and marketing of Xarelto. The judge also advised that there will be a small group of representative cases, or “bellwether” cases in the MDL who will prepare for trial in an attempt to get the matter before juries and gauge the likely overall response to the evidence presented. These early trial dates are not expected to begin until at least August 2016 and their outcomes will not be binding on future cases. In addition, the court will likely suggest the parties consider settlement prior to proceeding to trial.
HOW A XARELTO SETTLEMENT WOULD WORK
In settlement negotiations, the parties will look at what a jury would likely award to each individual case. Additionally, they will assess their relative strengths and weaknesses if the case were to go to trial. A plaintiff should consider the following factors in negotiating a settlement:
The severity and duration of the injury from Xarelto
Effects the Xarelto injury has had on the patient’s physical and mental health
Past and future pain and suffering
Cost of medical expenses as a result of the use of Xarelto
Amount of lost wages or loss of earning capacity
Loss sustained by family members as a result of the patient’s injuries from Xarelto
HAVE YOU BEEN INJURED BY XARELTO?
If you have suffered injuries as a result of taking Xarelto, contact us for a free consultation and case evaluation with one of our experienced personal injury attorneys. You may be entitled to compensation for the harms you’ve suffered.
http://www.ohiotiger.com/xarelto-lawsuit-progress-update/

Return to headline | Return to top
Xarelto Lawsuit Representation

Aug 28, 2015 | Cueria Law Firm L.L.C.

The Doctor/patient relationship is one based on a foundation of trust. When a pharmaceutical company takes advantage of this relationship and puts patients at risk, they should be held accountable. There are reasons that a new drug has many trials, to ensure that it actually does what the manufacturer claims. When a company fails to thoroughly test their product, they are risking the lives of their patients.
Xarelto, or Rivaroxaban, is an anticoagulant/blood thinner manufactured by Bayer that has been found to cause uncontrollable bleeding. Prescribed by doctors to patients at risk of heart attack or stroke, Xarelto is supposed to reduce a patient’s risk of blood clots. What’s become perfectly clear is that Xarelto is a dangerous drug and that patients have had adverse side effects they were not warned about. Unfortunately for some, the drug’s side effects have no cure and therefore, have proven to be life-threatening or fatal.
The pharmaceutical industry should not be allowed to make a profit through putting lives at risk. Serving the New Orleans and Gulf Coast area for over twenty years, Cueria Law Firm has successful experience in representing Xarelto settlements. The lawyers in New Orleans based Cueria law firm have the right expertise to represent you and get you the compensation you deserve. If you or a family member experienced Xarelto’s unwanted side effects, it’s important to take your case to court.
If you have been injured as a result of Xarelto, please call our lawyers in New Orleans for a free consultation at 800-899-7102.
http://www.cuerialawfirm.com/xarelto-lawsuit-representation/

Return to headline | Return to top
Bayer and Janssen Sued over Alleged Xarelto-related Complications

Aug 29, 2015 | Danziger & De Llano, LLP

Illinois – A consumer is suing the manufacturers of anticoagulant medication Xarelto over alleged damages attributed to the use of the product from 2011.
Daniel Hernandez, a Rhode Island resident, has filed a complaint against the following pharmaceutical companies: Janssen Ortho; Janssen Research and Development; Janssen Pharmaceuticals; and Bayer Corporation and several of its United States subsidiaries. The lawsuit was filed in February in the circuit court of St. Clair County.
The defendant businesses manufacture, distribute, and promote Xarelto as an effective and safe remedy for the risk of embolism and stroke, the suit states.
In 2013 June, the FDA sent a warning letter to the defendants asking them to stop promoting the product, the filing says. The plaintiffs claim that at least 100 reports have been filed so far in connection with Xarelto-related complications, including many deaths.
Daniel Hernandez says Xarelto does not have any antidote in the events of hemorrhagic strokes and other complications. Hernandez alleges that the defendant businesses failed to research the safety of the medication and to provide proper warning to physicians or its consumers of the associated risks. Additionally, the companies failed to honestly disclose their knowledge about severe side effects, the plaintiff alleges. The lawsuit accuses the defendants of violation of warranty, deception, negligence and fraud.
Citing personal sufferings and products liability, Daniel Hernandez is asking for more than 50,000 in damages, plus costs and attorney fees.
Janssen Global Services responded to the lawsuit, stating that Xarelto is an effective and vital anticoagulant use for reducing the risk of fatal blood clots. A Janssen spokesperson said the product has been prescribed to more than two million patients in the United States ever since it was introduced in the market. He says Xarelto’s benefit-risk profile remains fully favorable and consistent with clinical trials. The spokesman said all anticoagulants carry risks such as bleeding. The company has always warned of such risks, he said.
Xarelto, also called rivaroxaban, is the most recently introduced anticoagulant (blood thinner). This orally taken medication is supposed to prevent fatal blood clots which could obstruct the flow of blood to the important body organs. This anticoagulant was developed by pharmaceutical major Bayer and J&J’s New Jersey-based subsidiary Janssen Pharmaceuticals. When compared with older anticoagulants, Xarelto has some advantages. One of them is that the drug is prescribed in a uniform dose while the older medications require specific dose for each individual.
http://www.unitedprofessionals.org/bayer-and-janssen-sued-over-alleged-xarelto-related-complications/

Return to headline | Return to top
Xarelto MDL Gathers Steam

Aug 30, 2015 | LawyersandSettlements.com

By Heidi Turner

Anaheim, CA: If you thought the number of Xarelto lawsuits filed was about to slow down, you might have to think again. In the past month, another 400 or so lawsuits have been added to the Xarelto multidistrict litigation, alleging patients suffered serious Xarelto side effects, including uncontrolled bleeding.

According to court documents, 1,231 lawsuits have been consolidated for pretrial proceedings in MDL 2592 (In Re: Xarelto (Rivaroxaban) Products Liability Litigation) as of August 17, 2015. That’s up from 805 lawsuits consolidated as of July 15, 2015 and well up from the around 500 lawsuits consolidated in June. Consolidation of lawsuits is done when lawsuits share similar questions of fact and is not a comment on the merits of the individual suits.

In the case of Xarelto, lawsuits allege patients suffered serious bleeding events and were not adequately warned that use of Xarelto could result in uncontrolled bleeding.

Xarelto is a blood thinner, used to reduce the risk of blood clots and strokes. It is among a newer generation of anticoagulants and has been marketed as a safe and effective medication. Many patients have been prescribed Xarelto in place of warfarin (known by the brand name Coumadin) because it is reportedly easier to use and doesn’t require regular blood monitoring.

But critics argue that Xarelto patients should have their blood monitored because there is still a risk of uncontrolled bleeding. And when Xarelto came out, it did not come with an antidote to bleeding events. Warfarin, conversely, has an antidote in the form of vitamin K, so patients who developed bleeding events could be given vitamin K to counteract the blood thinning effects of warfarin.
Despite the lack of an antidote, Xarelto is also reportedly more expensive than warfarin. Critics maintain that Xarelto has no added benefit over warfarin and comes with a similar risk of serious bleeding events but with no antidote.

This means that relatively minor injuries could become serious for patients taking Xarelto, which is what lawsuits allege has happened. The maker of Xarelto has already faced a warning letter from the FDA (in 2013) for minimizing the risks associated with the medication.

The lawsuits are filed against Bayer and Janssen Pharmaceuticals, the makers of Xarelto, alleging the companies knew or should have known about the risks associated with their drug.
http://www.lawyersandsettlements.com/articles/xarelto/xarelto-lawsuit-death-bleeding-issue-24-20876.html#.VeRltPlVhBc

Return to headline | Return to top
The rise of Xarelto litigation

Aug 31, 2015 | APSense

By Mickey Andersonn

Since the filing of the first Xarelto lawsuit in January 2014, a large number of cases have been filed against the manufacturer of the blood-thinning drug. With so many lawsuits, the U.S. Judicial Panel decided to form a multi-district litigation mechanism to streamline the discovery phases of the litigation. At the time of the approval of the multi-district litigation, there were almost 21 lawsuits pending in 10 districts. As per the Judicial Panel on Multidistrict Litigation’s monthly report, almost 86 lawsuits were pending as of January 15, 2015, in multi-district litigation before US District Judge Eldon E. Fallon, in the Eastern District for Louisiana. In May 2015, a total number of 434 lawsuits had been filed, as against 33 in December 2014.
These numbers reveal an alarming trend: as the number of legal claims against Xarelto continues to grow, more and more people have been experiencing side effects from Xarelto. With regard to the lawsuits filed, the victims claim that were not warned by Bayer and Johnson & Johnson's Janssen Pharmaceutical Division – the blood thinner’s manufacturer – about the potential side effects and risks associated with Xarelto.
Even though blood thinning drugs usually have some side effects, as per these plaintiffs, Xarelto is a drug that causes life-threatening bleeding. Moreover, there is currently no antidote available for Xarelto users, which has unfortunately led to innumerable deaths.
Similarly, the lawsuits allege that Xarelto has been marketed as a one size fits all drug to boost sales. On the contrary, its advertisement should have been more accurate, with the pharmaceutical companies giving warnings about its monitoring and lack of antidote. Meanwhile, others stated that the defendants created Xarelto as an alternative to Warfarin, but it causes severe bleeding complications. In addition, Xarelto also costs more than Warfarin.
Nevertheless, in a similar case, litigation against the manufacturer of a similar drug, Pradaxa, was settled in May 2014. The total cost of litigation was $680 million to resolve about 4,000 bleeding claims. However, as per The Institute for Safe Medication Practices’ report releases in 2013, more patients had experienced fatal injuries from taking Xarelto than those who took Pradaxa.
Therefore, it is not surprising that the number of lawsuits filed against Xarelto is likely to rise in future. Unfortunately, all these lawsuits have a common theme of uncontrollable bleeding that leads to injury, hospitalization, or death. Some of the most common injuries named in lawsuits include heart attack, stroke, pulmonary embolism, rectal bleeding, brain hemorrhage, vaginal bleeding, epidural hematoma, and gastrointestinal bleeding.
Are you or a loved one suffering from bleeding complications after taking Xarelto? If so, you may be eligible to receive compensation for your losses. Contact The Meldofsky Firm for legal consultation. The firm will review your case to ensure that you get a fair compensation from a Xarelto lawsuit attorney.
http://www.apsense.com/article/the-rise-of-xarelto-litigation.html

Return to headline | Return to top
Xarelto Lawsuits Update: Texas Woman Files Lawsuit Against Xarelto Manufacturers

Aug 31, 2015 | The Legal Herald

By Marc Goldich

BloodThinnerHelp.com reports today on the latest developments in the Xarelto litigation. Recently, the manufacturers of Xarelto, Bayer AG and Johnson & Johnson’s pharmaceutical department, Janssen Pharmaceuticals, have been sued in federal court in the Eastern District of New York by a woman in Texas who alleges that because of the manufacturer’s lack of warning regarding Xarelto’s side effects and the lack of sufficient safety testing on the drug, she suffered serious injuries. The complaint is listed under federal court docket number 1:14-CV-04524 and has been transferred to the Xarelto MDL.
Lawsuit Alleges Manufacturers Concealed Xarelto Side Effects
The FDA approved Xarelto in 2011 for use in the United States. Since its approval, Xarelto has been marketed as a more convenient alternative to the traditionally prescribed blood thinner Warfarin because of Xarelto’s uniformed dosing and lack of required blood monitoring. Xarelto was approved to treat patients who suffered from atrial fibrillation, deep vein thrombosis, and in patients who have recently undergone knee or hip replacement surgeries. Despite these conveniences, as the complaint alleges, Xarelto’s manufacturers failed to warn doctors and patients that there is no antidote available to reverse the anti-coagulation effects that Xarelto causes, whereas the effects of Warfarin can be counteracted by administering Vitamin K.
In this case, the plaintiff was prescribed Xarelto by her doctor to prevent blood clots due to her heart condition known as atrial fibrillation. She was taking the blood thinner for five months when she suffered from a life threatening internal bleeding incident that left her with serious injuries. The complaint filed did not detail the exact injuries the plaintiff suffered but it did state that she was left with permanent injuries that will require future care that were a direct result of her uncontrollable internal bleeding.
Xarelto Lawsuit is Filed for Compensation
In the case of the plaintiff in this New York filed case, she is likely to have many medical expenses because of the life saving measures that were required to stop the bleeding and also expenses for the long term medical care needed because of her new condition. The plaintiff is also likely to file damages for loss of income, pain and suffering, and mental damage caused by the incident.

“We encourage all patients who have been harmed by Xarelto to speak with a lawyer about a potential lawsuit,” attorney Marc Goldich says, “By filing a lawsuit, you can begin the process of recovery and pursue justice for what you and your family endured through no fault of your own.”
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://legalherald.com/xarelto-lawsuits-update-texas-woman-files-lawsuit-against-xarelto-manufacturers/

Return to headline | Return to top
Xarelto Studies Point to Increased Bleeding Risk

Sep 2, 2015 | Top Class Actions

By Karina Basso

Researchers have published two new studies regarding the controversial anticoagulant medication Xarelto, raising more concerns about the uncontrollable bleeding side effects associated with the blood thinner.
Both of these recent Xarelto studies link the drug, manufactured by Janssen Pharmaceuticals, with bleeding side effects that can lead to fatal consequences for patients.
Background on Xarelto
In 2011, the FDA approved Xarelto as a blood clot treatment for patients who had recently undergone knee or hip replacement surgery. Later on, the agency approved the blood thinning medication as way to reduce the risk of stroke for individuals diagnosed with atrial fibrillation, as well as to treat other conditions like pulmonary embolism and deep vein thrombosis.
However, after just one year on the market, Xarelto was implicated in several adverse event reports that claimed patients suffered from various Xarelto injuries, including internal bleeding, blood clots, and pulmonary embolisms.
There are currently hundreds of Xarelto injury lawsuits pending in state and federal courts across the United States.
New Xarelto Studies Support Injury Reports
The first Xarelto study reports that three patients developed “spontaneous vitreous hemorrhage,” an eye bleeding condition that causes bleeding between the lens and the retina, soon after starting a Xarelto prescription.
According to Doctors Judy H. Hun and John C. Hwang, the authors of this Xarelto study, the Janssen anticoagulant is “increasingly prescribed as a replacement for warfarin sodium in the management of atrial fibrillation.” However, it seems that Xarelto may be associated with an increased risk of eye bleeding. This risk may be even higher for individuals switching from a different anticoagulant to Xarelto.
The second blood thinner study compared the “real world safety” of Xarelto and another popular anticoagulant, Pradaxa, to Warfarin, an older blood thinner. This study gathered and examined data from Oct. 1, 2010 through March 31, 2012, provided by a large administrative database housing information for commercially insured U.S. individuals.
The adult participants in this Xarelto study filled a drug prescription for either Xarelto, Pradaxa, or Warfarin during the study period. Of the 46,000 participants, 39,607 used Warfarin (Coumadin), 4,907 used Pradaxa, and 1,649 used Xarelto. Researchers found that all three drugs had a similar risk of gastrointestinal bleeding; however, the researchers cautioned that “we cannot rule out as much as a 50% increase in the risk of gastrointestinal bleeding with dabigatran (Pradaxa) compared with warfarin or a more than twofold higher risk of bleeding with rivaroxaban (Xarelto) compared with warfarin.”
Additional Xarelto Studies
Other Xarelto studies are particularly concerned with bleeding risks in certain patient populations. A 2015 Xarelto study examined Japanese patients and found that 29 of the 46 participants who filled a Xarelto prescription were at a higher risk of bleeding side effects. A second 2015 study suggested patients over the age of 75 were at a higher risk of bleeding when taking Xarelto.
The researchers of these Xarelto studies concluded that patients in these vulnerable groups should undergo regular blood monitoring when taking the blood thinner.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/101167-xarelto-studies-point-to-increased-bleeding-risk/

Return to headline | Return to top
Xarelto Dangers Outlined In Lawsuit

Sep 2, 2015 | American Injury Attorney Group

Xarelto lawyers note the Xarelto dangers that were outlined in allegations contained in a woman’s lawsuit filed against drug makers Janssen Pharmaceuticals and Bayer AG. The July 2015 lawsuit, filed in federal court for the Eastern District of New York, claims that the drug makers were negligent in failing to perform sufficient safety tests on the drug.
If you or a loved one took Xarelto and suffered complications, contact the American Injury Attorney Group today to learn more about your options. We can answer your questions in a free, confidential, no-obligation consultation, and if you wish to pursue a claim, we can connect you with an affiliated Xarelto lawsuit attorney.
Important: The time you have to pursue a claim is limited. Contact us for more information.
Woman Claims Xarelto Led To Internal Bleeding
Xarelto is a popular blood thinner which is widely used across the United States. According to a news report, the plaintiff was prescribed Xarelto by her doctor for the prevention of blood clots. After taking the drug for five months the plaintiff suffered an internal bleed which resulted in serious injury. The woman not only claims that the drug makers were negligent in failing to perform sufficient testing on the drug, but her lawsuit also alleges that the companies acted negligently by failing to warn the public of the dangerous side effects associated with Xarelto.
Xarelto has been prescribed more than 11 million times in the United States since its approval by the FDA in 2011. The news report also stated that uncontrollable internal bleeding is among the most serious side effect associated with Xarelto and has been reported by many patients prescribed to the drug.
Injured Patients May Be Entitled to Compensation
If a drug maker fails to fulfill its duty to provide safe drugs and to warn of potentially harmful side effects that may be associated with its medication, it could be held liable for any injuries that may result. Patients who have been injured by Xarelto may be entitled to compensation for damages, including:
Medical expenses
The permanency of the injury
Pain, suffering, and mental anguish
Loss of income or ability to work
If a patient dies from complications after taking Xarelto, his or her family members may be able to pursue claims for their loved one’s wrongful death. Compensation may include:
Pain, suffering, and mental anguish from the loss of a loved one
Loss of a loved one’s financial support
Funeral expenses
Affected patients are encouraged to speak with a Xarelto lawsuit attorney to learn more about their rights and remedies.
Contact Us For More Information
If you or a loved one took Xarelto and suffered complications, including internal bleeding, contact the American Injury Attorney Group for more information. You can fill out the form on this page, call us at the number listed at the top of the page, or email us at info@attorneygroup.com.
When you contact us, an attorney will follow up with you to speak with you about your case or answer questions that you might have. There is no cost or obligation to speak with us, and any information you provide will be kept confidential.
Please note that the law limits the time you have to pursue a claim for an injury. If you think you have a case, you should not delay taking action.
See our Frequently Asked Questions page for more information, and contact the American Injury Attorney Group today.
https://attorneygroup.com/blog/xarelto-dangers/

Return to headline | Return to top
FDA Reviewers: Warfarin is Better than Xarelto for Stroke Patients

Sep 2, 2015 | Meldofsky Firm

The blood thinner drug sold under the name Xarelto (Rivaroxiban) has been criticized by reviewers from the U.S. Food and Drug Administration (FDA) for what they’re calling a lack of efficacy in preventing stroke in certain patients.
Physicians prescribe Xarelto for stroke prevention in people with non-valvular atrial fibrillation or “AF”.
This conclusion was the result of a meeting of the FDA Cardiovascular and Renal Drugs Advisory Committee, a group that reviews prescription drugs and makes recommendations as to whether a particular medication should be approved for a specific indication or ailment.
Xarelto is a new generation anti-coagulant drug that’s known as an Xa inhibitor. The blood thinner medication inhibits a substance known as thrombin, which is, in part, responsible for the formation of blood clots. These blood clots can then travel to the lungs or brain, causing a deadly event such as a stroke or pulmonary embolism. Physicians prescribe Xarelto for stroke in patients who are at high risk of this potentially deadly condition.
FDA on Xarelto for Stroke Prevention in Atrial Fibrillation Patients
A number of FDA reviewers came down on Xarelto’s efficacy in preventing stroke in patients suffering from an irregular heartbeat condition known as non-valvular atrial fibrillation (AF). These individuals are at a much higher risk of experiencing a stroke or pulmonary embolism.
Blood thinners are typically prescribed to lower the patient’s stroke risk, but some have criticized Xarelto for its high risk of complications. Xarelto complications can include uncontrolled bleeding and even blood clots and stroke — the very conditions that the blood thinner is intended to prevent.
Drug manufacturer Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, even sponsored a study which has come to be known as the “Rocket-AF study.” This study involved over 14,000 patients who were diagnosed with non-valvular atrial fibrillation. Some were prescribed 20 mg of Xarelto daily, while others were prescribed Warfarin/Coumadin to lower the patients’ stroke risk.
The Rocket-AF study’s results suggested that when prescribing Xarelto for stroke patients, the drug was equally effective when compared to Warfarin/Coumadin – the traditional treatment for preventing stroke in patients with AF. The study results claimed that Xarelto was much easier for the patient, since it does not require the intensive blood monitoring and dietary change that is required while using Warfarin/Coumadin. The study results also claimed that the two drugs had a comparable major bleeding risk (a claim which has since been contradicted by newer studies which have found that Xarelto actually has a higher major bleeding risk than Warfarin/Coumadin.)
The FDA reviewers also criticized the study results for some glaring omissions, such as the fact that there is no antidote or reversal agent available for Xarelto. This makes major Xarelto bleeding incidents significantly more dangerous.
What’s more, the study ended 2 days after the patient’s last dosage. The study did not include data on the transitionary period whereby patients were transitioned from Xarelto to Warfarin/Coumadin — a notoriously risky process. In fact, one FDA reviewer indicated that Xarelto would need to perform a study focusing on the transitioning process.
Initially, it was claimed that Xarelto was superior to Warfarin/Coumadin for preventing strokes in patients with AF. But it was revealed that the cases where Xarelto appeared to be superior were “misleading” as improper Warfarin/Coumadin dosing may have skewed the results.
Ultimately, it was found that Xarelto was not superior but equal to Warfarin/Coumadin in terms of its efficacy. But once other factors were considered – such as the lack of antidote and potential study flaws – at least one FDA reviewer called Rivaroxiban inferior to Warfarin/Coumadin.
Notably, in order to receive FDA approval for the treatment of a specific condition or indication, a drug must prove that it is at least equally effective when compared to the existing drugs that are currently available on the market.
Xarelto did ultimately receive FDA approval for use in the prevention of stroke in patients with non- valvular atrial fibrillation. It’s also prescribed for reducing the risk of pulmonary embolism, deep-vein thrombosis and preventing deep-vein thrombosis in patients undergoing knee replacement or hip replacement procedures. But the drug remains quite controversial.
Uncontrolled Internal Bleeding and Xarelto
When it comes to Xarelto, strokes, uncontrolled bleeding and other serious complications have been reported. Major bleeding incidents may include stomach and other GI bleeds, colon bleeding, eye bleeding, brain bleeds and kidney (renal) bleeding.
A number of Xarelto studies have been performed. Some have revealed a 200% higher risk of bleeding when compared to Warfarin/Coumadin. And as mentioned above, there is no Xarelto antidote or reversal agent available.
Many patients and family members of deceased patients have filed Xarelto lawsuits on the basis that they were never informed of the drug’s risks and complications. Some have also criticized the drug makers, calling them irresponsible for releasing a medication that does not have an antidote or reversal agent available.
Legal Action for Xarelto Patients
Xarelto lawsuits now number in the hundreds, with over 1230 cases filed as of August 2015.
The sheer volume of Xarelto lawsuits has prompted the formation of a multi-district litigation (MDL) case. This is designed to simplify and accelerate pre-trial processes like discovery and evidence sharing for similar cases.
These 1200+ Xarelto MDL lawsuits are now in the Eastern District of Louisiana under the guidance of Judge Eldon Fallon. Bellwether trials are slated to begin in August 2016.
If you or a family member experienced major bleeding incident, or experienced a stroke while on Xarelto, you may have a right to receive financial compensation.
Contact the experienced and compassionate legal team here at The Meldofsky Firm. Call us today for a free, private case evaluation. Call (877) 274-8672.
http://xareltoinjurylawsuits.info/warfarin-better-than-xarelto-for-stroke-patients/

Return to headline | Return to top
Patient Questions Bleeding Side Effects With Blood Thinner Xarelto

Sep 3, 2015 | Righting Injustice

By Jennifer Walker-Journey

E.H., a healthy 79-year-old man, is questioning whether he should take the new blood thinner Xarelto to treat occasional atrial fibrillation considering his history with bleeding events.
“I hear it can be dangerous,” E.H. told Dr. Roach in a regular medical advice column in The Detroit News. “My doctors don’t seem worried, but I am.” E.H. says he has suffered from rectal bleeding in the past, “which wasn’t serious, but was scary.” He can’t even take aspirin because he’s prone to throwing up blood. He’s read enough about the new anticoagulant to question whether he should be concerned about taking Xarelto.
Xarelto is in a new class of blood thinners prescribed to patients with atrial fibrillation to reduce their risk of strokes caused by blood clots. The newer drugs are designed to replace the long-used anticoagulant warfarin. Xarelto and other drugs in this class are considered more convenient than warfarin because patients taking warfarin must be monitored on a regular basis to check the level of medication in their blood.
All blood thinners, including Xarelto and warfarin, increase a person’s risk of bleeding events including gastrointestinal bleeds and brain hemorrhages. With that in mind, Dr. Roach pointed out that the decision to take a blood thinner to prevent stroke in atrial fibrillation “is based on your benefits weighed against your risk.”
Warfarin is still an option and while it is more inconvenient than Xarelto, it does offer something that Xarelto does not – anantidote. When a bleeding emergency occurs in patients taking warfarin, a reversal agent can be given. No such antidote currently exists for Xarelto.
“Given a history of vomiting blood and rectal bleeding,” Dr. Roach advised E.H., “I would have a long talk with your doctor before making a decision.”
http://www.rightinginjustice.com/news/2015/09/03/patient-questions-bleeding-side-effects-with-blood-thinner-xarelto/

Return to headline | Return to top
Widow Files Xarelto Bleeding Wrongful Death Lawsuit

Sep 4, 2015 | Top Class Actions

By Ashley Vanover

Bayer and Johnson & Johnson are facing a wrongful death lawsuit, alleging that their blood thinner Xarelto (rivaroxaban) is dangerous and should not be sold.
A Florida widow filed a Xarelto bleeding wrongful death lawsuit on behalf of her deceased husband, Ronald H. against the manufacturer Janssen Pharmaceutical, a subsidiary of Johnson & Johnson and the co-marketer of Xarelto, and Bayer Healthcare AG, alleging these companies failed to warn of the increased risks of irreversible internal bleeding when using Xarelto.
According to the Xarelto lawsuit, Ronald started using Xarelto in 2012. In January 2013, Ronald suffered a bleeding episode that was allegedly a direct result of using Xarelto. His condition deteriorated after the internal bleeding event and he entered hospice care and died on May 8, 2013.
The Xarelto lawsuit claims that Bayer and Janssen continued to sell it even though they knew the dangerous risks. The Xarelto lawsuit further accuses the defendants of purposely concealing important safety information and failing to test the drug enough before it was put on the market.
Approved in 2011, Xarelto is one of the newest anticoagulants. Xarelto has been widely prescribed to prevent blood clots in patients suffering from atrial fibrillation (arrhythmia of the heart), deep vein thrombosis (deep blood clots), pulmonary bleeding, stroke, and in patients who have recently undergone a knee or hip replacement surgery.
It generally is prescribed as an alternative to Warfarin (coumadin), a blood thinner that began to be used in 1954. Vitamin K is coumadin’s reversal agent. Xarelto does not have one.
Other potential injuries caused through the use of Xarelto include thrombosis (blood clots), decreased hemoglobin (a substance that carries oxygen in red blood cells), cerebrovascular accidents (an event that leads to a cerebral hemorrhage), hematoma (a semisolid mass in the blood), peripheral edema (swelling of the lower limbs), and dyspnea (difficulty breathing).
The Xarelto Lawsuit is Case No. 3:15-cv-00554-MMH-MCR, in the U.S. District Court for the Middle District of Florida Jacksonville Division.
http://apco-engage.devbox15.com/edit-newsletter/1297

Return to headline | Return to top

Add recipients

Suggested